Intensifying competition, pricing pressure and copycat versions of its weight-loss drugs are holding back sales at the pharma ...

Eli Lilly and Novo Nordisk agreed to discount their GLP-1 medications from $1350 per month to around $245 to $350 per month.

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...

The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through ...

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...

Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the active ingredient in ...

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook ...

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

A Novo Nordisk executive collapsed during President Trump’s announcement about lowering the cost of weight loss drugs like ...

Below, doctors explain everything you need to know about the phenomenon. It’s important to be clear upfront that “Ozempic ...